Program
igrelimogene litadenorepvec
Its studies are mostly in Melanoma · Adenoviridae Infections · Lung Neoplasms, led by TILT Biotherapeutics.
Furthest: phase 2, since Feb 4, 20226 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TILT Biotherapeutics | 64 open or running | phase 2since Feb 4, 2022 | Dec 19, 2019 | Nov 2026phase 1 · NCT06961786 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 19, 2019First study: phase 1 study in MelanomaFirst studyNCT04217473 · 17 enrolled · Denmark, France
- Jan 4, 2021Phase 1 study in Adenoviridae InfectionsNCT04695327 · 32 enrolled · Finland
- Feb 1, 2022Phase 1 study in MelanomaNCT05222932 · 15 enrolled · United States, Finland
- Feb 4, 2022Phase 2 study in Adenoviridae InfectionsNCT05271318 · 29 enrolled · United States, Finland
- Oct 31, 2023Phase 1 study in Lung NeoplasmsNCT06125197 · 22 enrolled · United States
- Apr 23, 2025Phase 1 study in MelanomaNCT06961786 · 9 enrolled · Denmark
Ahead
- Nov 2026Primary completion: phase 1 study in MelanomaNCT06961786
- Dec 2026Primary completion: phase 1 study in MelanomaNCT05222932
- Mar 2027Primary completion: phase 2 study in Adenoviridae InfectionsNCT05271318
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06961786Melanoma · Denmark | 1 | Active, not recruiting | Nov 2026 | 9 |
| NCT06125197Lung Neoplasms · United States | 1 | Active, not recruiting | Jan 30, 2026 | 22 |
| NCT05271318Adenoviridae Infections · United States, Finland | 2 | Active, not recruiting | Mar 2027 | 29 |
| NCT05222932Melanoma · United States, Finland | 1 | Active, not recruiting | Dec 2026 | 15 |
| NCT04695327Adenoviridae Infections · Finland | 1 | Completed | Sep 3, 2025 | 32 |
| NCT04217473Melanoma · Denmark, France | 1 | Completed | Dec 12, 2023 | 17 |
How it is read
Names in the registry
- “TILT-123”, 6 entries
Conditions, from the studies’ own filings
- Melanoma, 3 studies
- Adenoviridae Infections, 2 studies
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.